

# Sex Hormone-regulated *CMG2* Is Involved in Breast and Prostate Cancer Progression

ZIQIAN FANG, CHARLOTTE KILLICK, CERITH HALFPENNY, NATASHA FREWER,  
KATHRYN A. FREWER, FIONA RUGE, WEN G. JIANG and LIN YE

*Cardiff China Medical Research Collaborative, Division of Cancer and Genetics,  
Cardiff University School of Medicine, Cardiff, U.K.*

**Abstract.** *Background/Aim:* Capillary morphogenesis gene 2 (*CMG2*) is involved in prostate and breast cancer progression. This study aimed to investigate sex hormone receptor-mediated regulation of *CMG2* in breast and prostate cancer, and its implication in disease progression. *Materials and Methods:* Expression of *CMG2*, oestrogen receptor (*ER*) and androgen receptor (*AR*) was determined in breast and prostate cancer cell lines, respectively, using real-time quantitative PCR (*QPCR*) and western blot. Association between *CMG2* and sex hormone receptors was analysed in a number of transcriptome datasets. Immunohistochemical staining was performed in tissue microarrays of breast cancer (*BR1505D*) and prostate cancer (*PR8011A*). *CMG2* expression was determined in 17 $\beta$ -oestradiol treated breast cancer cells and *AR* over-expressing prostate cancer cells. *Results:* *CMG2* was found to be inversely correlated with sex hormone receptors in breast and prostate cancer. Lower expression of *CMG2* was associated with a poor prognosis in *ER* (+) breast cancer but not *ER* (-) tumours. Both *ER* (+) breast cancer cell lines and *AR* (+) prostate cancer cell lines presented lower expression of *CMG2*, which was increased following sex hormone deprivation. Exposure to 17- $\beta$ -oestradiol and *AR* over-expression repressed *CMG2* expression in breast cancer and prostate cancer cell lines, respectively. *Conclusion:* *CMG2* is inversely correlated with *ER* and *AR* status in breast and prostate cancer, respectively. *ER* and *AR* mediate repression of *CMG2* expression in corresponding cancerous cells.

*Correspondence to:* Dr. Lin Ye, Cardiff China Medical Research Collaborative, Division of Cancer and Genetics, Cardiff University School of Medicine, Academic Avenue, Cardiff, CF14 4XN, U.K. Tel: +44 2920687861, e-mail: YeL@Cardiff.ac.uk

**Key Words:** *CMG2*, *ER*, *AR*, breast cancer, prostate cancer.



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0>).

Breast cancer is the most common type of cancer in the UK, accounting for 15% of all cancer cases. Biomarkers, such as the oestrogen receptor (*ER*), progesterone receptor (*PR*) and human epidermal growth factor 2 (*HER2*) hold great weight in breast cancer prognosis (1). *ER* expression determines the validity of therapeutic interventions and is the best indicator to a positive response with an endocrine therapy (2). Tamoxifen is only prescribed as a treatment in *ER* positive (*ER*+) breast cancer; it acts as a pro-drug that inhibits oestrogen-dependent cellular proliferation (3). Therefore, it is not effective as a treatment for *ER* negative (*ER*-) breast cancer.

Androgen receptor (*AR*) plays a pivotal role in the development of prostate and maintains its physiological function by transferring the signal from extracellular ligands to intracellular pathways (4). Deregulated *AR* has been implicated in prostate cancer and has been targeted by common therapies for both locally advanced lesions and the most advanced diseases either to reduce its ligands produced from testis and adrenal glands or interfere with *AR* using specific inhibitors such as enzalutamide (5). These therapies are effective for early-stage tumours. However, when prostate cancer cells adapt to androgen deprivation and restore *AR* signalling, castration-resistant prostate cancer (*CRPC*) develops (6), and furthermore, prolonged *AR* pathway inhibition could cause histological dedifferentiation, epithelial-mesenchymal transition (*EMT*) and neuroendocrine differentiation.

Capillary morphogenesis gene 2 (*CMG2*) also known as anthrax toxin receptor 2 (*ANTXR2*) encodes the type I transmembrane protein *CMG2*. Its extracellular domain mediates cell adhesion to extracellular matrix by binding to collagen IV laminin and fibronectin (7). *CMG2* is located on chromosome 4q, and encodes four different protein isoforms *CMG2*<sup>489</sup>, *CMG2*<sup>488</sup>, *CMG2*<sup>386</sup>, and *CMG2*<sup>322</sup> (8). These isoforms include vWA, Ig like, transmembrane and cytoplasmic domains. However, the *CMG2*<sup>322</sup> isotype is anticipated to be a secreted form as it lacks the transmembrane domain (8, 9). *CMG2* mutations are associated with juvenile hyaline fibromatosis (*JHF*) and infantile systemic hyalinosis (*ISH*). The *CMG2* mutations lie in the domain that is involved in the

extracellular matrix interaction, resulting in characteristic fibromatoses as hyaline accumulation in the dermis (10). *CMG2* has been shown to be up-regulated in human tumour endothelium. Furthermore, *CMG2* is thought to regulate endothelial cell proliferation and tubule formation (9, 11). In addition to its role in angiogenesis, our previous study of *CMG2* in prostate cancer showed that *CMG2* was able to enhance the adhesion and but inhibited invasiveness of prostate cancer cells (12). A study of serum levels of *CMG2* in prostate cancer patients showed increased *CMG2* levels in patients who developed distant metastases (13). A study of its role in breast cancer demonstrated that over-expression of *CMG2* inhibited the growth of breast cancer cells. Furthermore, reduced expression of *CMG2* in breast cancer was associated with shorter overall and relapse-free survival (14).

The progression and prognosis of both breast and prostate cancer are significantly associated with sex hormone receptors. Furthermore, based on our previous studies of *CMG2* in both prostate and breast cancer, we aimed to investigate whether sex hormone receptors regulate *CMG2* and whether deregulated *CMG2* is implicated in the progression of both breast and prostate cancer with a different status of these hormone receptors.

## Materials and Methods

**Cell lines and cell culture.** The human breast cancer cell lines MCF-7, MDA-MB-231, T47D, ZR751, BT474, MDA-MB-361, SKBR3, BT549, BT20, MDA-MB-468 and prostate cancer cell lines PC-3, DU-145, LNCaP, VCaP were purchased from ATCC (American type culture collection, Boulevard Manassas, VA, USA). LNCaP, VCaP, BT474, MDA-MB-361 cells were cultured RPMI 1640 medium (Sigma Aldrich, Poole, UK) with 10% foetal calf serum (FCS) and antibiotics, whilst other cell lines were cultured in DMEM-F12 medium (Sigma Aldrich) supplemented with 10% FCS and antibiotics. Polyclonal goat anti-human-*CMG2* (AF2940) antibody was obtained from R&D systems (Minneapolis, MN, USA).

**Immunohistochemical staining for *CMG2* in both prostate and breast cancer tissues.** Tissue microarrays of both prostate cancer (PR8011a) and breast cancer (BR1505d) were purchased from US Biomax, Inc (Rockville, MN, USA). Immunohistochemical staining for *CMG2* was performed using the VECTASTAIN® ABC Systems (Vector Laboratories, Oxfordshire, UK) and anti-*CMG2* antibody (1:50, Abcam, Cambridge, UK).

**AR over-expression in prostate cancer cell line.** PC-3 and DU-145 cells were transduced with lentiviral particles prepared from lentiviral vectors carrying the coding sequence of human AR gene or empty vector, respectively (Vector builder, Chicago, IL, USA). Lentiviral particles were packaged in HEK-293T cells (GenHunter, Nashville, TN, USA). The transduced cells were subject to a selection using puromycin (2 µg/ml) before they were subsequently maintained in medium containing 0.5 µg/ml of puromycin.

**RNA extraction, reverse transcription, and real time quantitative PCR (QPCR).** Total RNA was extracted from cells using TRI

reagent (Sigma-Aldrich). GoScript reverse transcription mix (Promega, Southampton, UK) was used for the reverse transcription. QPCR was employed to determine *CMG2* transcripts using Sybr Green master mix (Sigma Aldrich) and primers for *CMG2* (forward: 5'-CAGGATAGGTGCAGGACAAAGC and reverse: 5'-TCGGAATGGCAGTGTCTCTGC) and GAPDH (forward: 5'-TGCACCACCAACTGCTTAGC-3' and reverse: 5'-GGCATGGACTGTGGTCATGAG-3'). Fold Change was calculated using 2<sup>-ΔΔCT</sup> method (15). For conventional PCR, GoTaq Green Master Mix (Promega, Hampshire, UK) was applied using primers for AR (forward: 5'-TTACACCAAAGGGCTAGAAG and reverse: 5'-AGGGTACCACACATCAGGT-3') and GAPDH (forward: 5'-CTGAGTACGTCGGAGTC and reverse: 5'-GACTGTGGTCA TGAGTCCTT).

**Western blot analysis.** Cellular proteins were extracted with RIPA lysis buffer followed by a separation using SDS-PAGE before electrical transfer onto a nitrocellulose membrane. A blocking with 10% skimmed milk was conducted before incubating with a primary antibody and corresponding secondary antibody. Antibodies used were anti-GAPDH (1:4,000, Santa Cruz Biotechnology, Dallas, TX, USA), anti-AR (1:2,000, Santa Cruz Biotechnology), anti-*CMG2* (1:2,000, R&D Systems) and anti-Actin antibodies (1:4,000, R&D Systems). Secondary antibodies used include anti-mouse IgG (A5278, Sigma Aldrich) and anti-goat IgG (A8919, Sigma Aldrich). Protein bands were visualised using the Supersignal™ West Dura kit (Pierce Biotechnology, Rockford, IL, USA) and photographed with an UVITech imager (UVITech, Cambridge, UK).

**Treatment of cell lines with 17-β-oestradiol.** To remove endogenous serum steroids and any weak oestrogen activity, MCF-7 and MDA-MB-231 cells were washed twice with PBS and were subsequently cultured in 6-well plates in phenol red-free medium supplemented with 10% charcoal stripped foetal bovine serum (CS-FBS). After 24 h, cells were treated with 1nM 17-β-oestradiol for 4 and 24 h.

**Statistical analysis.** Mann-Whitney test was applied for non-normally distributed data, *t*-test was used for normally distributed data and Pearson's Chi-squared test was applied for analysing nominal data. Correlation between genes was analysed using Spearman test. All the statistical analyses were performed using SPSS software (version 26, SPSS, Chicago, IL, USA). Statistical significance was considered at *p*<0.05. Survival analysis was conducted using the KMplot (16).

## Results

***CMG2* expression in breast cancer is correlated with ER.** *CMG2* expression was first analysed in a GEO dataset of breast cancer (GSE20685, n=327). *CMG2* expression was lower in ER (+) breast tumours (n=204), *p*<0.05 compared with ER (-) tumours (n=123) (Figure 1A). In the same cohort, *CMG2* expression was inversely correlated with ER (Figure 1B). Our previous study showed that high *CMG2* expression is associated with better survival (14). To further determine whether this association is correlated with ER status, TCGA datasets (n=1044) were applied. In ER (+) tumours, *CMG2* tended to be reduced in locally advanced tumours according to the T stage




Figure 1. *Capillary morphogenesis gene 2 (CMG2)* is correlated with *oestrogen receptor (ER)* expression in breast cancer. (A) *CMG2* transcript levels in *ER (+)* and *ER (-)* breast cancers were analysed in the GEO Dataset GSE20685 using Mann–Whitney test. \* $p < 0.05$ . (B) Correlation between *CMG2* and *ESR1 (E $\alpha$ )* in a cohort of breast cancer (GSE20685) was analysed using Spearman test. In TCGA dataset ( $n = 1,044$ ), *CMG2* expression levels were evaluated in both *ER (+)* tumours (C,  $n = 805$ ) and *ER (-)* tumours (D,  $n = 236$ ). (E) Representative images of the *CMG2* immunohistochemistry (IHC) staining taken from *ER(+)* samples of breast cancer tumours at different T stages. Association with overall survival (OS) was analysed in both *ER (+)* tumours (F,  $n = 221$ , cut off value = 15) and *ER (-)* tumours (G,  $n = 284$ , cut off value = 30) using the KMplot ([www.kmplot.com](http://www.kmplot.com)). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

(Figure 1C). However, such a change was not observed in the *ER (-)* tumours (Figure 1D), suggesting *ER* may play a role in regulating *CMG2*. Neither *ER (+)* nor *ER (-)* tumours exhibited differential expression of *CMG2* according to lymph node metastasis and distant metastases (data not shown). To validate the *CMG2* protein expression, immunohistochemical staining for *CMG2* was performed in the tissue microarray of breast cancer (BR1505D). In *ER (+)* breast cancer tumours, *CMG2* expression was decreased in tumours with a later T stage (T3 and T4) (Table I and Figure 1E). Furthermore, lower *CMG2* expression was associated with poorer overall survival (OS) in patients with *ER (+)* tumours (Figure 1F) but not in those with *ER (-)* tumours (Figure 1G).

*CMG2* expression is regulated by oestrogen in breast cancer cells. Expression of *CMG2* in a panel of breast cancer cell lines was determined using both QPCR (Figure 2A) and western blot (Figure 2B). *CMG2* mRNA is highly expressed in three triple negative breast cancer (TNBC) cell lines (MDA-

MB-231, BT549 and BT20). Moderate expression was seen in a TNBC cell line (MDA-MB-468) and a HER2 positive cell line (HCC1419). *CMG2* was lowly expressed or absent from *ER (+)* cell lines (MCF-7, ZR751, BT474 and MDA-MB-361) and another HER2 positive cell line (SKBR3). *CMG2* protein was more abundant in MDA-MB-231 cells and moderately expressed in BT549 cells but absent or just detectable in other cell lines (Figure 2B). Expression of *CMG2* transcripts in another panel of breast cancer cell lines was also evaluated in the CCLC dataset (Cancer Cell Line Encyclopaedia=44) (17). *CMG2* was inversely correlated with the *ER* expression in the breast cancer cell lines (Figure 2C). Exposure to 17- $\beta$ -oestradiol for 24 h resulted in an approximately 50% reduction of *CMG2* transcripts in MCF-7 cells in comparison with its expression in the control and cells treated with 17- $\beta$ -oestradiol for 4 h (Figure 2D). Furthermore, analysis of *CMG2* expression in *ER $\alpha$* -silenced MCF7 cells (GSE27473, *CMG2*: 238050\_at) showed increased expression of *CMG2* compared with the control (Figure 2E).

Table I. *Capillary morphogenesis gene 2 (CMG2) immunohistochemistry (IHC) staining in breast tumours with different oestrogen receptor (ER) expression and different T stage.*

ER status	T stage	CMG2 stain strength				p-Value
		Negative	Weak	Moderate	Strong	
ER (-)	T1&T2	22 (41.5%)	16 (30.1%)	13 (24.5%)	2 (3.8%)	0.655
	T3&T4	20 (52.6%)	8 (21.1%)	7 (18.4%)	3 (7.9%)	
ER (+)	T1&T2	18 (42.9%)	12 (28.6%)	10 (23.8%)	2 (4.8%)	0.015
	T3&T4	14 (87.5%)	0 (0%)	2 (13.5%)	0 (0%)	

*CMG2* is associated with prostate cancer progression especially for AR positive tumours. Thomas *et al.* found *CMG2* transcript levels were up-regulated in metastatic prostate cancer compared with the primary tumour (13). To further validate this at the protein expression level, immunohistochemical staining for *CMG2* was carried out in the tissue microarray of prostate cancer (PR8011A). Decreased staining for *CMG2* was observed in the tumours in comparison with both normal prostate tissues and adjacent normal prostatic tissues (Figure 3A and B). Furthermore, our analysis of *CMG2* expression in primary prostate tumours showed marked down-regulation of *CMG2* in primary tumours (GSE3325) that developed distant metastases (n=6),  $p < 0.05$ , compared with its expression in tumours without distant metastasis (n=13) (Figure 3C). Similarly, reduced expression of *CMG2* was also observed in metastatic tumours (GSE6919) from prostate cancer in comparison with its expression in primary tumours (Figure 3D). The implication of *CMG2* in the disease progression was also analysed in TCGA prostate cancer cohort according to different AR status. Analyses of its transcripts using RNA sequencing data showed that *CMG2* was reduced in tumours that had lymph node metastasis but only in tumours with higher AR expression (Figure 3E). More interestingly, in tumours with higher AR expression, down-regulation of *CMG2* was observed in tumours with a Gleason score greater than 7 (Figure 3F).

*AR* mediates a repression on *CMG2* expression in AR positive prostate cancer cells. The down-regulation of *CMG2* was observed in AR highly expressing prostate cancers that developed lymph node metastases and those with a higher Gleason score. Correlation between *CMG2* and *AR* was analysed in a gene array data of prostate cancer (GSE6919) comprising normal prostate tissues (n=17), adjacent normal prostate tissues (n=60), prostate primary tumours (n=66) and metastatic tumours (n=25). This analysis showed an inverse correlation between these two genes at the transcript level (Figure 4A). Quantitative analysis of *CMG2* transcripts showed that AR positive prostate cancer

cell lines (LNCaP and VCaP) had lower expression of *CMG2* compared with the two AR negative prostate cancer cell lines (PC-3 and DU-145) (Figure 4B). PC-3 and DU-145 cell lines over-expressing AR, which was verified using conventional PCR (Figure 4C) and western blot (Figure 4D), exhibited reduced expression of *CMG2* (Figure 4E). Furthermore, *CMG2* expression was increased in the AR positive LNCaP cells when they were deprived from steroid hormones using charcoal stripped serum (Figure 4F).

### Discussion

It has been shown that *CMG2* is down-regulated in breast cancer and its reduced expression is associated with poor prognosis (14). To date, ER is one of the pivotal markers for characterising the disease, predicting prognosis, and treating the disease. In the present study, a decrease in *CMG2* was evident in the more locally advanced ER (+) tumours but not in ER (-) breast cancers. This suggests that there is an association between ER and *CMG2* in breast cancer and *CMG2* is likely involved in the progression of the disease. Further analysis showed that *CMG2* was inversely correlated with ER $\alpha$ . In line with the inverse correlation observed in breast cancer tumours, ER positive breast cancer cell lines also exhibited lower expression of *CMG2* in comparison with the ER negative breast cancer cell lines, suggesting ER may mediate repression of *CMG2* expression in breast cancer cells. Indeed, 17- $\beta$ -oestradiol down-regulated *CMG2* expression in MCF7 cells. This is also supported by the finding that ER $\alpha$  silencing in MCF7 cells resulted in increased expression of *CMG2*. However, in our previous study, an ER $\alpha$  agonist (PPT, Propyl pyrazole triol) increased *CMG2* expression in MCF7 cells, which was prevented by a specific antagonist (MPP, methyl-piperidino-pyrazole) (14). The exact effect of these ER selective regulators on gene expression in comparison with natural oestrogens and their application in the treatment of the disease are yet to be fully investigated. In addition, the reduced *CMG2* expression in ER positive breast cancers was also associated with poorer overall survival in patients with ER positive tumours. Our




Figure 2. *Capillary morphogenesis gene 2 (CMG2)* expression is regulated by oestrogen in breast cancer cells. (A) *CMG2* transcripts were quantitatively analysed in breast cancer cell lines using *QPCR*. Fold change in gene expression calculated using the  $2^{-\Delta\Delta CT}$  method. (B) *CMG2* protein levels in the breast cancer cell lines were analysed using western blot. (C) Correlation between *CMG2* and *ESR1* (*ERα*) was analysed in breast cancer cell line data collected from the *CCL*E dataset using Spearman test. (D) *CMG2* expression in MCF-7 cells treated with  $17\beta$ -oestradiol ( $1\text{ nM}$ ) was quantified using *QPCR*. (E) *CMG2* expression in *ERα*-silenced MCF-7 cells with ( $n=3$ ) (GSE27473, *CMG2*: 238050\_at) was also analysed in comparison with the control ( $n=3$ ). \* $p<0.05$ , \*\* $p<0.01$ , \*\*\* $p<0.001$ .

previous study also showed that *CMG2* over-expression can inhibit both proliferation and invasion of MCF7 cells (14). Taken together, the reduced *CMG2* expression in ER positive breast cancer enhances proliferation and invasiveness of breast cancer cells and thus contributes to the disease progression and poor prognosis. Further investigation will shed light on the role of *CMG2* in ER positive breast cancer and the corresponding endocrine therapy.

AR is essential to maintain the physiological functions and development of prostate and is also involved in carcinogenesis, disease progression and management of prostate cancer, which have been intensively investigated for decades (18). Our previous study showed that *CMG2* is expressed in both normal prostate and prostate cancerous tissues (8). In the current study, immunohistochemical staining showed reduced expression of *CMG2* in metastatic tumours from prostate cancer in comparison with primary tumours. Similar to the ER, AR is also a classical nuclear

receptor. The finding of ER-mediated repression of *CMG2* in breast cancer inspired us to investigate whether AR also mediates the regulation of *CMG2* in prostate cancer thus contributing to disease progression. Compared with AR (–) prostate tumours, lower *CMG2* expression was associated with lymph node metastasis and a higher Gleason score in AR (+) prostate cancers, suggesting that AR-associated down-regulation of *CMG2* is involved in the progression of prostate cancer being similar to the role of ER-regulated *CMG2* in breast cancer. Further analysis showed that *CMG2* is also inversely correlated with AR in the prostate cancer tumours. This inverse correlation was also evident in the quantitative analysis of *CMG2* transcripts in prostate cancer cell lines, which showed a lower expression of *CMG2* in AR (+) prostate cancer cell lines (LNCaP and VCaP). In order to demonstrate whether the difference in *CMG2* expression was due to the presence of AR, AR was forcibly over-expressed in AR (–) cell lines PC-3 and DU-145.




Figure 3. Capillary morphogenesis gene 2 (CMG2) is associated with the progression of androgen receptor (AR)+ prostate cancer. (A) Immunohistochemical staining for CMG2 was performed on a tissue microarray (PR8011a, Biomax) comprising tumours (T), adjacent normal prostatic tissues (AN), and normal prostate tissues (N). (B) Representative images taken from normal, adjacent normal and tumour samples. (C) Expression of ANTXR2 was analysed in a gene expression array dataset (GSE3325, CMG2ANTXR2 gene ID: 238050\_at, GSE3325). Expression of ANTXR2 was observed in localised primary prostate tumours in comparison with its expression in benign prostate tissues, whilst a further reduction was seen in primary tumours which developed distant metastases. (D) Expression of ANTXR2 in metastases of prostate cancer was analysed in a gene array GEO dataset (GSE6919, CMG2ANTXR2 gene ID: 58617\_at, GSE6919). (E) Implication of CMG2 in lymph node metastasis was analysed in tumours of TCGA dataset. The tumours were separated into two groups: AR-high and AR-low groups according to AR expression (cut off value=400.39). (F) Association between CMG2 and Gleason score was also analysed in tumours with different AR expression.




Figure 4. Androgen receptor (AR) mediates a regulation of capillary morphogenesis gene 2 (CMG2) in prostate cancer cells. (A) Correlation between CMG2 and AR as analysed in a gene array dataset (GSE6919, CMG2:51714\_at, AR: 52851\_at). (B) Expression of CMG2 in AR positive prostate cancer cell lines (LNCaP and VCaP), and AR negative cell lines (PC-3 and DU-145) was determined using QPCR. Fold changes in CMG2 transcripts normalised against GAPDH. AR was over-expressed in both PC-3 and DU-145 cell lines using empty lentiviral vectors or lentiviral vectors carrying the coding sequence of human AR, which is named as AR exp. The expression of AR was determined using both conventional PCR (C) and western blot (D). (E) CMG2 expression was determined in both PC-3 and DU-145 cell lines with AR over-expression using QPCR. (F) CMG2 expression in LNCaP cells following a 24-h deprivation from steroid hormones using charcoal stripped serum was determined using QPCR. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

CMG2 transcripts were decreased significantly following the AR over-expression. This is further supported by the finding of increased CMG2 expression in the LNCaP cells under androgen deprivation. It suggests that AR mediated repression of CMG2 expression in prostate cancer cells, which is similar to the ER-mediated regulation of CMG2 in breast cancer.

### Conclusion

To date, little is known about the mechanism CMG2 deregulation in malignant tumours. The present study

demonstrated for the first time that both ER and AR mediate the down-regulation of CMG2 in breast and prostate cancer, respectively. Sex hormone receptors mediate the down-regulation of CMG2, which is involved in disease progression. Further investigation will highlight its potential in the disease management of both breast cancer and prostate cancer when endocrine therapy is applied.

### Conflicts of Interest

The Authors have no conflicts of interest to declare in relation to this study.

## Authors' Contributions

LY designed the study. ZF, CK, CH and FR performed the experiments. ZF, CK, CH, WGJ and LY performed data analyses. NF and KF evaluated and analysed the IHC staining. ZF, FR, WGJ and LY prepared the manuscript. CK, CH, NF, KF, FR, WGJ and LY revised and proofread the article.

## References

- 1 Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X and Giuliano AE: Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. *JAMA Surg* 149(2): 125-129, 2014. PMID: 24306257. DOI: 10.1001/jamasurg.2013.3181
- 2 Lumachi F, Brunello A, Maruzzo M, Basso U and Basso SM: Treatment of estrogen receptor-positive breast cancer. *Curr Med Chem* 20(5): 596-604, 2013. PMID: 23278394. DOI: 10.2174/092986713804999303
- 3 Martínez de Dueñas E, Ochoa Aranda E, Blancas Lopez-Barajas I, Ferrer Magdalena T, Bandrés Moya F, Chicharro García LM, Gómez Capilla JA, Zafra Ceres M, de Haro T, Romero Llorens R, Ferrer Albiach C, Ferriols Lisart R, Chover Lara D, López Rodríguez A, Munárriz Ferrandis J and Olmos Antón S: Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype. *Breast* 23(4): 400-406, 2014. PMID: 24685597. DOI: 10.1016/j.breast.2014.02.008
- 4 Huggins C and Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *CA Cancer J Clin* 22(4): 232-240, 1972. PMID: 4625049. DOI: 10.3322/canjclin.22.4.232
- 5 Jamroze A, Chatta G and Tang DG: Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. *Cancer Lett* 518: 1-9, 2021. PMID: 34118355. DOI: 10.1016/j.canlet.2021.06.006
- 6 Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. *Nat Rev Cancer* 15(12): 701-711, 2015. PMID: 26563462. DOI: 10.1038/nrc4016
- 7 Cryan LM and Rogers MS: Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. *Front Biosci (Landmark Ed)* 16(4): 1574-1588, 2011. PMID: 21196249. DOI: 10.2741/3806
- 8 Scobie HM, Rainey GJ, Bradley KA and Young JA: Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. *Proc Natl Acad Sci USA* 100(9): 5170-5174, 2003. PMID: 12700348. DOI: 10.1073/pnas.0431098100
- 9 Cryan LM and Rogers MS: Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. *Front Biosci (Landmark Ed)* 16(4): 1574-1588, 2011. PMID: 21196249. DOI: 10.2741/3806
- 10 Liu S, Leung HJ and Leppla SH: Characterization of the interaction between anthrax toxin and its cellular receptors. *Cell Microbiol* 9(4): 977-987, 2007. PMID: 17381430. DOI: 10.1111/j.1462-5822.2006.00845.x
- 11 Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, Tschantz WR, Zhang XM, Saha S, Fleming T and St Croix B: TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. *Cancer Cell* 21(2): 212-226, 2012. PMID: 22340594. DOI: 10.1016/j.ccr.2012.01.004
- 12 Ye L, Sanders AJ, Sun PH, Mason MD and Jiang WG: Capillary morphogenesis gene 2 regulates adhesion and invasiveness of prostate cancer cells. *Oncol Lett* 7(6): 2149-2153, 2014. PMID: 24932305. DOI: 10.3892/ol.2014.2038
- 13 Greither T, Marcou M, Fornara P and Behre HM: Increased soluble CMG2 serum protein concentration is associated with the progression of prostate carcinoma. *Cancers (Basel)* 11(8): 1059, 2019. PMID: 31357506. DOI: 10.3390/cancers11081059
- 14 Ye L, Sun PH, Malik MF, Mason MD and Jiang WG: Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis. *J Cancer Res Clin Oncol* 140(6): 957-967, 2014. PMID: 24667935. DOI: 10.1007/s00432-014-1650-2
- 15 Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 25(4): 402-408, 2001. PMID: 11846609. DOI: 10.1006/meth.2001.1262
- 16 Györfy B: Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. *Comput Struct Biotechnol J* 19: 4101-4109, 2021. PMID: 34527184. DOI: 10.1016/j.csbj.2021.07.014
- 17 Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, Barretina J, Gelfand ET, Bielski CM, Li H, Hu K, Andreev-Drakhlin AY, Kim J, Hess JM, Haas BJ, Aguet F, Weir BA, Rothberg MV, Paolella BR, Lawrence MS, Akbani R, Lu Y, Tiv HL, Gokhale PC, de Weck A, Mansour AA, Oh C, Shih J, Hadi K, Rosen Y, Bistline J, Venkatesan K, Reddy A, Sonkin D, Liu M, Lehar J, Korn JM, Porter DA, Jones MD, Golji J, Caponigro G, Taylor JE, Dunning CM, Creech AL, Warren AC, McFarland JM, Zamanighomi M, Kauffmann A, Stransky N, Imielinski M, Maruvka YE, Cherniack AD, Tsherniak A, Vazquez F, Jaffe JD, Lane AA, Weinstock DM, Johannessen CM, Morrissey MP, Stegmeier F, Schlegel R, Hahn WC, Getz G, Mills GB, Boehm JS, Golub TR, Garraway LA and Sellers WR: Next-generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 569(7757): 503-508, 2019. PMID: 31068700. DOI: 10.1038/s41586-019-1186-3
- 18 Heinlein CA and Chang C: Androgen receptor in prostate cancer. *Endocr Rev* 25(2): 276-308, 2004. PMID: 15082523. DOI: 10.1210/er.2002-0032

Received August 11, 2022

Revised August 22, 2022

Accepted August 23, 2022